US 2023/0144186 A1 · QUININE AND ITS USE TO GENERATE INNATE IMMUNE RESPONSE

Abstract

The invention provides methods and compositions for assaying infectivity of viruses and potential treatments of such viruses in the upper respiratory tract using an air-liquid interface model with nasal epithelium cells; and treatment of viral infections of the upper respiratory tract by treating with bitter taste receptor agonists that stimulate NO production and/or antimicrobial protein production.

Claims14

Dependent claims

A method of treating a viral infection in a subject having an upper respiratory infection, comprising:

dispersing as particulate a formulation of a bitter taste receptor agonist;
applying the dispersed formulation onto the mucosal surface of an upper respiratory cavity of the subject;
and
generating NO production or stimulating antimicrobial peptide production, or both, through the stimulation of bitter taste receptors.

1 more element

Dependencies are inferred from the claim text.

Facts

Application

17/996,853Filed 21 Apr 2021

Priority

21 Apr 2020

Published

11 May 2023

Term ends

Not estimatedThe source records don’t support an estimate.

Classification11 codes

A61K 31/49
Quinolines; Isoquinolines: cinchonan derivatives, e.g. quinine
A61K 9/0043
Galenical forms characterised by the site of application: nose
A61P 11/00
Drugs for disorders of the respiratory system
A61P 31/14
Antivirals: for RNA viruses

Quinine and its use to generate innate immune response

Life of this patent

Quinine and its use to generate innate immune response

Life of this patent

Abstract

Claims14